BridgeMD
Comparing the Efficacy and Safety of Aspirin Alone versus Aspirin and Fondaparinux in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI)
EU CTIS ID: 2024-517229-18-00
What this study is testing
To compare efficacy in patients treated with aspirin alone compared to combination therapy with fondaparinux and aspirin prior to early invasive strategy in patients with NSTEMI.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of NSTEMI verified by: Rise or/and fall in cardiac troponin and symptoms of acute schema or ECG-changes compatible with acute schema
- Age > 18 years of age
- Expected remaining lifespan > 1 year
- Independent capacity to act and provide informed written and oral consent
You likely can't join if
- Treatment with any anticoagulants before enrollment and randomization
- Indication for acute CAG before enrollment and randomization, such as STEMI or patients classified as "Very High Risk" according to ESC 2023 Guidelines
- Not possible with CAG and PCI within 72 hours
- Unsuitable for CAG and possible PCI due to poor condition
- Estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2
- Known liver disease
See the full eligibility criteria
- Diagnosis of NSTEMI verified by: Rise or/and fall in cardiac troponin and symptoms of acute schema or ECG-changes compatible with acute schema
- Age > 18 years of age
- Expected remaining lifespan > 1 year
- Independent capacity to act and provide informed written and oral consent
- Treatment with any anticoagulants before enrollment and randomization
- Indication for acute CAG before enrollment and randomization, such as STEMI or patients classified as "Very High Risk" according to ESC 2023 Guidelines
- Not possible with CAG and PCI within 72 hours
- Unsuitable for CAG and possible PCI due to poor condition
- Estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2
- Known liver disease
- Endocarditis
- Active bleeding or high risk of bleeding where treatment with Fondaparinux is contraindicated
- Anemia (B-Hemoglobin < 6.0 mmol/l)
- Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.